Matthew Mei
City of Hope Medical Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Matthew Mei as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:52 UTC. Open this list on ClinicalTrials.gov
- Early Ph1NCT07395050 · Autologous CD6-CAR Treg Cells for Patients With Stage 3 Type 1 DiabetesCity of Hope Medical Center · not yet recruiting · Stage 3 Type 1 Diabetes · principal investigator
- Ph2NCT07275216 · Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard TreatmentCity of Hope Medical Center · recruiting · Classic Hodgkin Lymphoma · principal investigator
- Ph2NCT06453044 · Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular LymphomaCity of Hope Medical Center · recruiting · Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma · principal investigator
- Ph2NCT05718869 · Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL StudyCity of Hope Medical Center · active not recruiting · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma · principal investigator
- Ph1NCT05162976 · CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or RelapsedCity of Hope Medical Center · active not recruiting · Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma · principal investigator
- Ph1/Ph2NCT05152459 · Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular LymphomaCity of Hope Medical Center · withdrawn · Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma · principal investigator
- Ph2NCT01267812 · Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell TransplantationCity of Hope Medical Center · completed · Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma · principal investigator
- Ph2NCT00577278 · A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and MelphalanCity of Hope Medical Center · completed · Graft Versus Host Disease, Leukemia, Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:52 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 6 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Leadership, Planning and EvaluationP30CA033572 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI JOHN D. CARPTEN · fiscal years 2008 to 2026
- Hematopoietic Cell Transplantation for Hematologic MalignanciesP01CA030206 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI Stephen J Forman · fiscal years 2008 to 2010Named on NCT00577278
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:52 UTC. The ranking covers the 200 most relevant of 35 PubMed records, and a shared surname and initials can bring in a namesake. All 35 on PubMed
- Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.N Engl J Med · 2024230 citationsRCR 27.8
- Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies.Clin Cancer Res · 2021187 citationsRCR 9.1
- 107 citationsRCR 6.4
- An ex vivo study of arrested primary teeth caries with silver diamine fluoride therapy.J Dent · 2014103 citationsRCR 6.6
- Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma.Clin Cancer Res · 202075 citationsRCR 3.1
- Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.Ann Oncol · 201857 citationsRCR 1.7
- Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia.Br J Haematol · 201954 citationsRCR 1.9
- 49 citationsRCR 1.6
- High resource hospitalizations among children with vaso-occlusive crises in sickle cell disease.Pediatr Blood Cancer · 201245 citationsRCR 1.7
- Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial.Lancet Haematol · 202342 citationsRCR 3.4